Blueprint Medicines has received $50 million in Series C funding led by Partner Fund Management. The capital will be used to advance the company's two lead candidates through clinical trials and fund the development of its kinase discovery platform and pipeline. Its candidates set for clinical trials in 2015 are BLU-285, a mastocytosis and stomach tumor treatment, and BLU-554, a drug tailored for hepatocellular carcinoma. In total, Blueprint has raised $115 million in VC since its founding; existing investors include Fidelity Biosciences, Third Rock Ventures, Wellington Management and others. It received a valuation of $88 million in its previous funding, a $25 million Series B in January.